ArticleJournal of thoracic disease2025
Efficacy and safety of ceftazidime-avibactam versus standard antibiotic therapy for resistant Gram-negative bacterial infections: a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant Methods: A comprehensive search and retrieval of academic sources pertaining to the treatment of drug-resistant Results: A total of 2,203 publications were identified, and 8 studies were deemed eligible for analysis. The findings from the meta-analysis revealed that in comparison to the standard antibiotic treatment group, the CAZ-AVI group exhibited superior clinical efficacy and a higher rate of bacterial clearance. There was a decrease in adverse reactions and mortality in the CAZ-AVI group. Nevertheless, no statistically significant variances were observed in procalcitonin (PCT) and C-reactive protein (CRP) levels between the two groups. Sensitivity analysis indicated the stability and reliability of the combined effect size results. Conclusions: Ceftazidime and avibactam show superior clinical effectiveness and safety in managing drug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.